Sorry, you need to enable JavaScript to visit this website.

DEPO-SUBQ PROVERA 104® (medroxyprogesterone acetate injectable suspension) Drug Interactions

7 DRUG INTERACTIONS

7.1 Effect of Other Drugs on Depo-subQ provera 104

Moderate or Strong CYP3A Inducers

Concomitant use with moderate or strong CYP3A inducers may decrease concentrations of medroxyprogesterone acetate which may reduce depo-subQ provera 104 efficacy. This effect is based upon the primary metabolism of medroxyprogesterone acetate by CYP3A and was not confirmed by a clinical study.

Avoid coadministration of depo-subQ provera 104 with moderate or strong CYP3A inducers. Some examples of moderate CYP3A inducers are bosentan, efavirenz, etravirine, and modafinil. Some examples of strong CYP3A inducers are rifampin, carbamazepine, phenytoin, phenobarbital, mitotane, and St. John's wort (the CYP3A4 induction effect of St. John's wort varies widely and is preparation dependent). These examples are a guide and do not represent a comprehensive list of all possible drugs that may fit these categories.

The use of CYP3A inducers may require using a back-up or alternate contraceptive method.

What's New

No Current Announcements.

Contact Pfizer Medical

Search

Please enter your search term(s) for DEPO-SUBQ PROVERA 104®